Abstract
The introduction of highly active antiretroviral therapy in 1995 dramatically decreased AIDS-related events and deaths rates; however, the enthusiasm among the medical and social community was soon limited by the growing incidence of various side-effects that often greatly limited patients' quality of life. The second problem caused by such a complex treatment consisted of sub-optimal adherence, with a consequent higher risk of the development of drug resistance.
MeSH terms
-
Adult
-
Antiretroviral Therapy, Highly Active / adverse effects
-
Antiretroviral Therapy, Highly Active / methods*
-
CD4 Lymphocyte Count
-
Chronic Disease
-
Cohort Studies
-
Didanosine / administration & dosage
-
Drug Administration Schedule
-
Female
-
HIV Infections / drug therapy*
-
HIV Protease Inhibitors / administration & dosage
-
Humans
-
Male
-
Middle Aged
-
RNA, Viral / analysis
-
Reverse Transcriptase Inhibitors / administration & dosage
-
Viral Load
-
Zidovudine / administration & dosage
Substances
-
HIV Protease Inhibitors
-
RNA, Viral
-
Reverse Transcriptase Inhibitors
-
Zidovudine
-
Didanosine